Patents

US 8980942 B2: Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Granted
2015-03-17
Filed
2012-07-23 application 13555741
Type
Utility · 17 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC. One embodiment described herein relates to the transdermal administration of a Δ9-THC prodrug for treating and preventing diseases and/or disorders.

Source: PVGPATDIS, file of 2026-04-10 (ipg150317.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
ZYNERBA PHARMACEUTICALS, INC. 13 patentsUS company or organizationRadnor, PAZYNERBA PHARMACEUTICALS, INC. Federal lobbying client EXACT high confidence: identical full name and state
ZYNERBA PHARMACEUTICALS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Audra Lynn StinchcombLexington, KY15PVGPATDIS, file of 2026-04-10
Miroslaw Jerzy GolinskiLexington, KY12PVGPATDIS, file of 2026-04-10
Dana Carmel HammellGeorgetown, KY10PVGPATDIS, file of 2026-04-10
Jeffrey Lynn HowardLexington, KY6PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C07DHeterocyclic compoundsC07D311/80PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K9/0014PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P1/00PVGPATDIS, file of 2026-04-10
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or telluriumC07F9/65522PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-05-18Correction
Supplemental confirmatory grant of security interest in united states patents
HARMONY BIOSCIENCES MANAGEMENT, INC. (F/K/A ZYNERBA PHARMACEUTICALS, INC.) signed 2026-05-04JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT CHICAGO, IL75642/639PASDL, file of 2026-10-15
2014-12-11Name change
Change of name
ALLTRANZ INC. signed 2014-08-04ZYNERBA PHARMACEUTICALS, INC. RADNOR, PA34477/690ECORSEXC, file of 2026-09-25
2014-10-13Release of security interest
Release of security interest
KENTUCKY ECONOMIC DEVELOPMENT FINANCE AUTHORITY signed 2014-09-24ZYNERBA PHARMACEUTICALS, INC. NEW YORK, NY33937/742ECORSEXC, file of 2026-09-25
2014-10-13Name change
Change of name
ALLTRANZ, INC. signed 2014-08-05ZYNERBA PHARMACEUTICALS, INC. NEW YORK, NY33937/246ECORSEXC, file of 2026-09-25
2014-01-13Assignment
Conditional assignment
ALLTRANZ, INC. signed 2012-12-13KENTUCKY ECONOMIC DEVELOPMENT FINANCE AUTHORITY FRANKFORT, KY31950/443ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.